“…[188][189][190] MDL1 * P33310 695 Peptides [191,192] STE6 P12866 1290 a-factor [193,194] S. pombe HMT1 * Q02592 830 Phytochelatin conjugated Cd2+ [195,196] MAM1 P78966 1336 M-factor [195,196] ABCC Collectively, P-gp, MRP1 and ABCG2 act as brothers in arms to ensure the physiological detoxification of endogenous metabolites as well as exogenous xenobiotics across most epithelial barriers, including placenta, testis, mammary epithelium, liver and GI tract as well as the blood-brain barrier [119,139,146,152,206]. However, how, and sometimes even if, they actually cause clinical MDR in cancer has remained a highly controversial issue, often subject to intense discussions in the field [102,207]. As for microbial anti-infective MDR, it has been generally accepted though that bacterial ABC transporters [208][209][210][211][212] and fungal PDR transporters [124,[213][214][215][216] are key causes for clinical MDR, often setting an unsurmountable roadblock in antimicrobial treatments [10,101,[217][218][219].…”